Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 28.3% | (60,249.7%) | (87.7%) | (143.5%) | 350.4% | 187.6% | (259.3%) | (54.1%) | (60.1%) | (37.0%) | (20.0%) | (31.9%) | (26.0%) | (14.3%) | (23.5%) | 13.1% | 36.4% | 7.6% | 15.6% | 25.8% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 30.9%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for DexCom, Inc. have been 19.7% over the past three years, and 18.2% over the past five years.
As of today, DexCom, Inc.'s Return on Equity (ROE) is 30.9%, which is higher than industry median of (22.6%). It indicates that DexCom, Inc.'s Return on Equity (ROE) is Good.